Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety of ChimeriVax-JE Vaccine in Adults
NCT00314132Phase 3Completed
- Sponsor
- Sanofi
- Start
- Oct 2005
- Primary completion
- Nov 2006
- Modality
- Live Attenuated Vaccines
- Countries
- 2
01
Overview
Phase 3, randomised, double-blind trial in Japanese encephalitis (JE) comparing Placebo with ChimeriVax-JE (2 arms). Primary endpoints: Number of Participants Reporting Treatment Related Adverse Events Post Vaccination and Number of Participants Reporting Treatment Emergent Local Adverse Reactions and Treatment Emergent Systemic Reactions. Started Oct 2005; status: completed.
02
Drugs
japanese encephalitis chimeric virus vaccine
03
Conditions
Japanese encephalitis (JE)
Beyond the preview
Go deeper on NCT00314132.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00314132.